G2 repair and evaluation of the cytogenetic damage induced by low doses of X-irradiation during G0 in human lymphocytes.
In the present study two cytogenetic parameters were used to evaluate the DNA damage induced by low doses (1 up to 40 rad) of X-ray irradiation in G0 human lymphocytes. These parameters were the frequency of chromosomal lesions in G2 and the length of this cell cycle phase. The frequency of chromosomal lesions in G2 was determined by scoring the number of chromosomal aberrations in G0 irradiated lymphocytes post treated with two inhibitors of G2 repair mechanisms: caffeine and 3-aminobenzamide. A dose-dependent increase in chromosomal aberrations yield was detected in G0 lymphocytes X-ray irradiated with or without post treatment with these two DNA repair inhibitors during G2. Nevertheless, the dose response in this latter condition was higher than the one detected in control cells, indicating that the increase of irradiation dose in G0 lymphocytes produces an increment in the number of DNA lesions arriving to be repaired in G2. The analysis of the dose-response relationships for G2 length showed an statistically significant X-ray dose-dependent increase (G2 delay) from 2.5 up to 40 rad and a positive correlation between G2 delay and the frequency of chromosomal lesions in G2. These results suggest that the DNA lesions induced by low doses of X-irradiation in G0 lymphocytes may be higher than that detected by the standard method (control conditions) and may be responsible for an increase in G2 length. We propose, therefore, that an analysis of these two cytogenetic parameters can improve the evaluation of the DNA damage induced by low doses of X-rays irradiation in G0 cells.
Pincheira
J V
JV
Departamento de Biología Celular y Genética, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Lopez
I H
IH
Tapia
G O
GO
Navarrete
M H
MH
Oyarzun
C C
CC
D000293:Adolescent; D000328:Adult; D001549:Benzamides / Q000494:pharmacology; D002110:Caffeine / Q000494:pharmacology; D004249:DNA Damage; D004260:DNA Repair / Q000235:genetics*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D016195:G2 Phase / Q000235:genetics / Q000528:radiation effects*; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects / Q000528:radiation effects*; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D016192:Resting Phase, Cell Cycle / Q000235:genetics / Q000528:radiation effects*; D014965:X-Rays / Q000009:adverse effects
D001549:Benzamides; D004791:Enzyme Inhibitors; D010726:Phosphodiesterase Inhibitors; D002110:Caffeine; C025160:3-aminobenzamide